1. Home
  2. WLYB vs NAMS Comparison

WLYB vs NAMS Comparison

Compare WLYB & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WLYB
  • NAMS
  • Stock Information
  • Founded
  • WLYB 1807
  • NAMS 2019
  • Country
  • WLYB United States
  • NAMS Netherlands
  • Employees
  • WLYB N/A
  • NAMS N/A
  • Industry
  • WLYB Books
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • WLYB Consumer Discretionary
  • NAMS Health Care
  • Exchange
  • WLYB Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • WLYB 2.4B
  • NAMS 2.5B
  • IPO Year
  • WLYB N/A
  • NAMS N/A
  • Fundamental
  • Price
  • WLYB N/A
  • NAMS $19.85
  • Analyst Decision
  • WLYB
  • NAMS Strong Buy
  • Analyst Count
  • WLYB 0
  • NAMS 8
  • Target Price
  • WLYB N/A
  • NAMS $42.88
  • AVG Volume (30 Days)
  • WLYB 1.8K
  • NAMS 1.0M
  • Earning Date
  • WLYB 06-17-2025
  • NAMS 08-06-2025
  • Dividend Yield
  • WLYB 3.20%
  • NAMS N/A
  • EPS Growth
  • WLYB N/A
  • NAMS N/A
  • EPS
  • WLYB 1.53
  • NAMS N/A
  • Revenue
  • WLYB $1,677,609,000.00
  • NAMS $47,140,000.00
  • Revenue This Year
  • WLYB $1.75
  • NAMS N/A
  • Revenue Next Year
  • WLYB $2.40
  • NAMS N/A
  • P/E Ratio
  • WLYB $27.55
  • NAMS N/A
  • Revenue Growth
  • WLYB N/A
  • NAMS 586.97
  • 52 Week Low
  • WLYB $37.27
  • NAMS $14.06
  • 52 Week High
  • WLYB $52.90
  • NAMS $27.29
  • Technical
  • Relative Strength Index (RSI)
  • WLYB 59.09
  • NAMS 52.90
  • Support Level
  • WLYB $44.65
  • NAMS $17.97
  • Resistance Level
  • WLYB $45.41
  • NAMS $19.13
  • Average True Range (ATR)
  • WLYB 0.72
  • NAMS 1.04
  • MACD
  • WLYB 0.43
  • NAMS -0.03
  • Stochastic Oscillator
  • WLYB 84.65
  • NAMS 35.63

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: